TY - JOUR
T1 - Characterizing Cortical Oscillatory Responses in Major Depressive Disorder Before and After Convulsive Therapy
T2 - A TMS-EEG Study
AU - Hill, Aron T.
AU - Hadas, Itay
AU - Zomorrodi, Reza
AU - Voineskos, Daphne
AU - Fitzgerald, Paul B.
AU - Blumberger, Daniel M.
AU - Daskalakis, Zafiris J.
N1 - Funding Information:
ATH is supported by an Alfred Deakin Postdoctoral Research Fellowship. In the last 5 years, ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. His-work was supported by the Ontario Mental Health Foundation, the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health, and the Temerty Family and Grant Family and through the center for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. DMB has received research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for two investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. DV has received research training fellowship funding from the Ontario Mental Health Foundation, the APA Eli Lilly research fellowship and a CAMH Postdoctoral Fellowship, and support from the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario. PBF is supported by a Practitioner Fellowship grant from National Health and Medical Research Council (1,078,567). In the last 3 years PBF has received equipment for research from Magventure A/S, Medtronic Ltd, Neurosoft and Brainsway Ltd. He has served on a scientific advisory board for Bionomics Ltd and LivaNova and is a founder and director of TMS Australia. RZ and IH have nothing to disclose. The authors report no additional conflicts.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/5/15
Y1 - 2021/5/15
N2 - Background: Combined transcranial magnetic stimulation and electroencephalography (TMS-EEG) is emerging as a powerful technique for interrogating neural circuit dysfunction in psychiatric disorders. Here, we utilized time-frequency analyses to characterize differences in neural oscillatory dynamics between subjects with major depressive disorder (MDD) and healthy controls (HC). We further examined changes in TMS-related oscillatory power following convulsive therapy. Methods: Oscillatory power was examined following TMS over the dorsolateral prefrontal and motor cortices (DLPFC and M1) in 38 MDD subjects, and 22 HCs. We further investigated how these responses changed in the MDD group following an acute course of convulsive therapy (either magnetic seizure therapy [MST, n = 24] or electroconvulsive therapy [ECT, n = 14]). Results: Prior to treatment, MDD subjects exhibited increased oscillatory power within delta, theta, and alpha frequency bands with TMS-EEG over the DLPFC, but showed no differences to HCs with stimulation over M1. Following MST, DLPFC stimulation revealed attenuated baseline-normalized power in the delta and theta bands, with reductions in the delta, theta, and alpha power following ECT. TMS over M1 revealed reduced delta and theta power following ECT, with no changes observed following MST. An association was also observed between the treatment- induced change in alpha power and depression severity score. Limitations: Limitations include the modest sample size, open-label MST and ECT treatment designs, and lack of a placebo condition. Conclusions: These results provide evidence of alterations in TMS-related oscillatory activity in MDD, and further suggest modulation of oscillatory power following ECT and MST.
AB - Background: Combined transcranial magnetic stimulation and electroencephalography (TMS-EEG) is emerging as a powerful technique for interrogating neural circuit dysfunction in psychiatric disorders. Here, we utilized time-frequency analyses to characterize differences in neural oscillatory dynamics between subjects with major depressive disorder (MDD) and healthy controls (HC). We further examined changes in TMS-related oscillatory power following convulsive therapy. Methods: Oscillatory power was examined following TMS over the dorsolateral prefrontal and motor cortices (DLPFC and M1) in 38 MDD subjects, and 22 HCs. We further investigated how these responses changed in the MDD group following an acute course of convulsive therapy (either magnetic seizure therapy [MST, n = 24] or electroconvulsive therapy [ECT, n = 14]). Results: Prior to treatment, MDD subjects exhibited increased oscillatory power within delta, theta, and alpha frequency bands with TMS-EEG over the DLPFC, but showed no differences to HCs with stimulation over M1. Following MST, DLPFC stimulation revealed attenuated baseline-normalized power in the delta and theta bands, with reductions in the delta, theta, and alpha power following ECT. TMS over M1 revealed reduced delta and theta power following ECT, with no changes observed following MST. An association was also observed between the treatment- induced change in alpha power and depression severity score. Limitations: Limitations include the modest sample size, open-label MST and ECT treatment designs, and lack of a placebo condition. Conclusions: These results provide evidence of alterations in TMS-related oscillatory activity in MDD, and further suggest modulation of oscillatory power following ECT and MST.
KW - Electroconvulsive therapy
KW - Magnetic seizure therapy
KW - Major depressive disorder
KW - Oscillations
KW - Tms-eeg
UR - http://www.scopus.com/inward/record.url?scp=85103081439&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2021.03.010
DO - 10.1016/j.jad.2021.03.010
M3 - Article
C2 - 33774319
AN - SCOPUS:85103081439
SN - 0165-0327
VL - 287
SP - 78
EP - 88
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -